LT2539366T - Protofibriles surišantys antikūnai ir jų panaudojimas parkinsono ligos, demencijos su levi kūneliais ir kitų alfa-sinukleinopatijų terapiniuose ir diagnostiniuose būduose - Google Patents
Protofibriles surišantys antikūnai ir jų panaudojimas parkinsono ligos, demencijos su levi kūneliais ir kitų alfa-sinukleinopatijų terapiniuose ir diagnostiniuose būduoseInfo
- Publication number
- LT2539366T LT2539366T LTEP11713058.3T LT11713058T LT2539366T LT 2539366 T LT2539366 T LT 2539366T LT 11713058 T LT11713058 T LT 11713058T LT 2539366 T LT2539366 T LT 2539366T
- Authority
- LT
- Lithuania
- Prior art keywords
- protofibril
- synucleinopathies
- dementia
- parkinson
- alpha
- Prior art date
Links
- 206010067889 Dementia with Lewy bodies Diseases 0.000 title 1
- 201000002832 Lewy body dementia Diseases 0.000 title 1
- 208000032859 Synucleinopathies Diseases 0.000 title 1
- 238000002405 diagnostic procedure Methods 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54306—Solid-phase reaction mechanisms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/30—Psychoses; Psychiatry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/30—Psychoses; Psychiatry
- G01N2800/302—Schizophrenia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/38—Pediatrics
- G01N2800/385—Congenital anomalies
- G01N2800/387—Down syndrome; Trisomy 18; Trisomy 13
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Optics & Photonics (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30863810P | 2010-02-26 | 2010-02-26 | |
| US40626010P | 2010-10-25 | 2010-10-25 | |
| PCT/IB2011/050826 WO2011104696A1 (en) | 2010-02-26 | 2011-02-25 | Protofibril-binding antibodies and their use in therapeutic and diagnostic methods for parkinson's disease, dementia with lewy bodies and other alpha-synucleinopathies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT2539366T true LT2539366T (lt) | 2018-04-25 |
Family
ID=44227520
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEP11713058.3T LT2539366T (lt) | 2010-02-26 | 2011-02-25 | Protofibriles surišantys antikūnai ir jų panaudojimas parkinsono ligos, demencijos su levi kūneliais ir kitų alfa-sinukleinopatijų terapiniuose ir diagnostiniuose būduose |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US8632776B2 (enExample) |
| EP (1) | EP2539366B1 (enExample) |
| JP (1) | JP5894939B2 (enExample) |
| CN (3) | CN110655573B (enExample) |
| AU (1) | AU2011219414B2 (enExample) |
| CA (1) | CA2789963C (enExample) |
| CY (1) | CY1120014T1 (enExample) |
| DK (1) | DK2539366T3 (enExample) |
| ES (1) | ES2661925T3 (enExample) |
| HR (1) | HRP20180230T8 (enExample) |
| HU (1) | HUE038313T2 (enExample) |
| LT (1) | LT2539366T (enExample) |
| NO (1) | NO2539366T3 (enExample) |
| PL (1) | PL2539366T3 (enExample) |
| PT (1) | PT2539366T (enExample) |
| RS (1) | RS57029B1 (enExample) |
| RU (1) | RU2555526C2 (enExample) |
| SI (1) | SI2539366T1 (enExample) |
| SM (1) | SMT201800044T1 (enExample) |
| WO (1) | WO2011104696A1 (enExample) |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3470079A1 (en) | 2008-04-29 | 2019-04-17 | BioArctic AB | Antibodies and vaccines for use in therapeutic and diagnostic methods for alpha-synuclein-related disorders |
| ES2661925T3 (es) | 2010-02-26 | 2018-04-04 | Bioarctic Ab | Anticuerpos de unión a las protofibrillas y su uso en métodos terapéuticos diagnósticos para la enfermedad de Parkinson, la demencia con cuerpos de Lewy y otras alfa-sinucleinopatías |
| US10989718B2 (en) * | 2014-09-11 | 2021-04-27 | Amprion, Inc. | Detection of misfolded alpha synuclein protein |
| PT2663579T (pt) | 2011-01-14 | 2017-07-28 | Univ California | Terapêutica de anticorpos contra a proteína r0r-1 e métodos para sua utilização |
| KR20200014441A (ko) * | 2012-01-20 | 2020-02-10 | 젠자임 코포레이션 | 항cxcr3 항체 |
| US9534044B2 (en) * | 2013-02-28 | 2017-01-03 | United Arab Emirates University | Alpha-synuclein antibodies and uses thereof |
| CA2924268C (en) | 2013-11-21 | 2021-05-18 | F. Hoffmann-La Roche Ag | Anti-alpha-synuclein antibodies and methods of use |
| JO3537B1 (ar) * | 2014-07-10 | 2020-07-05 | Bioarctic Neuroscience Ab | أجسام مضادة لييفية أولية لاميلويد بيتا الببتيد ab المحسنة |
| EP3207057A2 (en) | 2014-10-16 | 2017-08-23 | F. Hoffmann-La Roche AG | Anti-alpha-synuclein antibodies and methods of use |
| US10494425B2 (en) * | 2015-02-24 | 2019-12-03 | Rpeptide, Llc | Anti-amyloid-beta antibodies |
| EP3091087A1 (en) | 2015-05-08 | 2016-11-09 | Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol | Method for in vitro diagnosis of synucleinopathies using alpha-synuclein gene transcripts |
| GB201512203D0 (en) | 2015-07-13 | 2015-08-19 | Lundbeck & Co As H | Agents,uses and methods |
| US11327080B2 (en) | 2015-07-21 | 2022-05-10 | BioArctic Neruoscience AB | Method for treatment of traumatic brain injury targeting aggregated peptides |
| CA3004498A1 (en) | 2015-11-09 | 2017-05-18 | Neil R. Cashman | Amyloid beta epitopes and antibodies thereto |
| EP3374379A4 (en) | 2015-11-09 | 2019-05-15 | The University Of British Columbia | N-TERMINAL EPITOPES IN AMYLOID BETA AND CONFORMATION-SELECTIVE ANTIBODIES |
| JP7448174B2 (ja) | 2015-11-09 | 2024-03-12 | ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア | アミロイドベータ中間領域エピトープおよびそれに対する立体配座選択的抗体 |
| AU2017228474C1 (en) | 2016-03-04 | 2024-03-28 | Abmuno Therapeutics Llc | Antibodies to TIGIT |
| US10160800B2 (en) * | 2016-06-02 | 2018-12-25 | Medimmune Limited | Antibodies to α-synuclein and uses thereof |
| SG10201912842VA (en) * | 2016-07-14 | 2020-02-27 | Bioarctic Ab | Brain delivery protein |
| KR102550991B1 (ko) | 2016-07-18 | 2023-07-04 | 더 유니버시티 오브 브리티쉬 콜롬비아 | 아밀로이드 베타에 대한 항체 |
| US20180125920A1 (en) | 2016-11-09 | 2018-05-10 | The University Of British Columbia | Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions |
| MA46836A (fr) | 2016-11-15 | 2019-09-25 | H Lundbeck As | Agents, utilisations et procédés pour le traitement d'une synucléinopathie |
| CN110072888B (zh) | 2016-12-16 | 2023-07-18 | H.隆德贝克有限公司 | 药剂、用途和方法 |
| US10364286B2 (en) | 2016-12-22 | 2019-07-30 | H. Lundbeck A/S | Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation |
| EP3567054A4 (en) * | 2017-01-06 | 2021-03-10 | ABL Bio Inc. | ANTI-ALPHA SYN ANTIBODIES AND USES THEREOF |
| MX2019008029A (es) * | 2017-01-06 | 2019-12-11 | Abl Bio Inc | Anticuerpo anti-alfa-sinucleina y su uso. |
| EP3583124A1 (en) * | 2017-02-17 | 2019-12-25 | Bristol-Myers Squibb Company | Antibodies to alpha-synuclein and uses thereof |
| US20200148780A1 (en) * | 2017-04-21 | 2020-05-14 | Implicit Bioscience Pty Ltd | Cd 14 antagonist antibodies for treating neurodegenerative diseases |
| WO2018204352A1 (en) * | 2017-05-01 | 2018-11-08 | The Trustees Of The University Of Pennsylvania | Monoclonal antibodies against alpha-synuclein fibrils |
| EP3635393A4 (en) | 2017-05-16 | 2021-03-10 | Claudio Soto-Jara | ABNORMALLY FOLDING TAU PROTEIN DETECTION |
| US12286469B2 (en) | 2017-07-18 | 2025-04-29 | The University Of British Columbia | Humanized antibodies binding to amyloid-beta (A-beta) |
| BR112020001970A2 (pt) | 2017-08-02 | 2020-08-04 | Stressmarq Biosciences Inc. | anticorpo que se liga à alfa-sinucleína ativa |
| WO2019040617A1 (en) | 2017-08-23 | 2019-02-28 | The Trustees Of The University Of Pennsylvania | MONOCLONAL ANTIBODIES AGAINST PATHOLOGICAL ALPHA-SYNUCLEIN AND METHODS USING SAME |
| RU2657763C1 (ru) * | 2017-09-12 | 2018-06-15 | федеральное государственное бюджетное образовательное учреждение высшего образования "Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова" Министерства здравоохранения Российской Федерации | Способ диагностики болезни паркинсона |
| AU2018370279B2 (en) * | 2017-11-17 | 2022-11-03 | Abl Bio Inc. | Antibodies to a-synuclein and uses thereof |
| JP7212391B2 (ja) | 2017-12-14 | 2023-01-25 | エービーエル バイオ インコーポレイテッド | ａ－ｓｙｎ／ＩＧＦ１Ｒに対する二重特異抗体およびその用途 |
| GB201720970D0 (en) | 2017-12-15 | 2018-01-31 | Ucb Biopharma Sprl | Antibodies |
| GB201720975D0 (en) * | 2017-12-15 | 2018-01-31 | Ucb Biopharma Sprl | Anti-alpha synuclein antibodies |
| PL3728567T3 (pl) | 2017-12-19 | 2023-11-13 | Chase Therapeutics Corporation | Metoda oceny synukleinopatii |
| CN111630382A (zh) * | 2017-12-21 | 2020-09-04 | H.隆德贝克有限公司 | α-共核蛋白病的测定、方法和治疗 |
| CN109957547A (zh) * | 2017-12-25 | 2019-07-02 | 深圳宾德生物技术有限公司 | 一种靶向cd317的嵌合抗原受体t细胞及其制备方法和应用 |
| CN109957546A (zh) * | 2017-12-25 | 2019-07-02 | 深圳宾德生物技术有限公司 | 一种靶向cd317的嵌合抗原受体t细胞及其制备方法和应用 |
| US20210093670A1 (en) * | 2018-04-04 | 2021-04-01 | University Of Florida Research Foundation, Inc. | Materials and methods for the treatment of lewy body disorders |
| US20200017596A1 (en) * | 2018-05-10 | 2020-01-16 | Abvision, Inc. | Monoclonal antibodies activating cd40 and uses thereof |
| WO2020009482A1 (ko) * | 2018-07-03 | 2020-01-09 | 에이비엘바이오 주식회사 | 항 알파-시누클레인 항체 및 그 용도 |
| AU2019309938A1 (en) | 2018-07-24 | 2021-03-11 | Eisai R&D Management Co., Ltd. | Methods of treatment and prevention of alzheimer's disease |
| KR20210081356A (ko) * | 2018-10-19 | 2021-07-01 | 얀센 백신스 앤드 프리벤션 비.브이. | 항-시누클레인 항체 |
| TW202039562A (zh) * | 2018-12-12 | 2020-11-01 | 大陸商上海藥明生物技術有限公司 | 抗tim-3抗體及其用途 |
| RU2703430C1 (ru) * | 2018-12-13 | 2019-10-16 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр глазных болезней имени Гельмгольца" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ ГБ им. Гельмгольца" Минздрава России) | Способ прогнозирования развития нейродегенеративных заболеваний, в основе патогенеза которых лежит гамма-синуклеинопатия |
| TWI734279B (zh) * | 2018-12-14 | 2021-07-21 | 美商美國禮來大藥廠 | 抗α-突觸核蛋白抗體及其用途 |
| EP3946266A4 (en) * | 2019-03-28 | 2023-07-12 | The Chinese University Of Hong Kong | SUMO PEPTIDES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES |
| EP3963047A4 (en) * | 2019-04-30 | 2023-06-21 | Chase Therapeutics Corporation | ALPHA SYNUCLEIN ASSAYS |
| US20220291240A1 (en) * | 2019-08-27 | 2022-09-15 | The Johns Hopkins University | Biomarkers for neurodegenerative disorders |
| EP4084827A4 (en) | 2019-12-31 | 2024-01-10 | Chase Therapeutics Corporation | KINASES AS BIOMARKERS FOR NEURODEGENERATIVE DISEASES |
| CN111171152B (zh) * | 2020-01-15 | 2023-04-18 | 吉林医药学院 | Pcsk9抗体及其制备方法和应用 |
| NL2025332B1 (en) * | 2020-04-10 | 2021-10-26 | Syngle Therapeutics B V | Novel alpha-synuclein binding antibodies, or antigen binding portions thereof. |
| KR20230019152A (ko) | 2020-06-02 | 2023-02-07 | 아르커스 바이오사이언시즈 인코포레이티드 | Tigit에 대한 항체 |
| PH12022552829A1 (en) * | 2020-06-26 | 2023-06-14 | Bioarctic Ab | Alpha-synuclein protofibril-binding antibodies |
| US20230365665A1 (en) | 2020-09-17 | 2023-11-16 | Qatar Foundation For Education, Science And Community Development | ANTIBODY COMPOSITIONS TARGETING NON-PHOSPHORYLATED a-SYNUCLEIN AGGREGATES |
| JP2024525559A (ja) | 2021-07-09 | 2024-07-12 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | アルツハイマー病治療用バイオマーカー |
| WO2023034230A1 (en) | 2021-08-30 | 2023-03-09 | Eisai R&D Mangement Co., Ltd. | Subcutaneous formulations of anti-abeta protofibril antibody and methods of use thereof |
| AU2022439338A1 (en) | 2022-02-02 | 2024-08-15 | Eisai R&D Management Co., Ltd. | Methods of treatment using p-tau181 level |
| JP2023132247A (ja) * | 2022-03-10 | 2023-09-22 | 公立大学法人大阪 | シヌクレイノパシー検出用バイオマーカー及びその利用 |
| CN117430686B (zh) * | 2022-07-22 | 2025-07-01 | 深圳市安群生物工程有限公司 | α-突触核蛋白抗原表位肽及测定唾液中SNCA试剂盒和在帕金森病诊断中的应用 |
| CN116589567B (zh) * | 2022-11-30 | 2024-03-19 | 西南大学 | 马铃薯x病毒单克隆抗体pvx-2及其应用 |
| WO2025245381A1 (en) | 2024-05-23 | 2025-11-27 | The Trustrees Of Dartmouth College | Methods and compositions for enhancing the persistence of car expressing tregs in the cns and other tissues |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002519702A (ja) | 1998-07-03 | 2002-07-02 | イノジェネティックス・ナムローゼ・フェンノートシャップ | 神経変性の分別診断 |
| UA81216C2 (en) | 1999-06-01 | 2007-12-25 | Prevention and treatment of amyloid disease | |
| EP1309341A2 (en) | 2000-07-07 | 2003-05-14 | Lars Lannfelt | Prevention and treatment of alzheimer's disease |
| US20060018918A1 (en) | 2000-12-27 | 2006-01-26 | Board Of Regents, The University Of Texas System | Production of stabilized conformational isomers of disease associated proteins |
| US8506959B2 (en) | 2002-11-01 | 2013-08-13 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
| US20080014194A1 (en) * | 2003-10-31 | 2008-01-17 | Elan Pharmaceuticals, Inc. | Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease |
| TW200509968A (en) * | 2002-11-01 | 2005-03-16 | Elan Pharm Inc | Prevention and treatment of synucleinopathic disease |
| US7358331B2 (en) | 2003-05-19 | 2008-04-15 | Elan Pharmaceuticals, Inc. | Truncated fragments of alpha-synuclein in Lewy body disease |
| UA93653C2 (ru) * | 2003-11-07 | 2011-03-10 | Иммунекс Корпорейшн | Выделенное антитело, kotopoe специфически связывается c человеческим рецептором il-4 (il-4r) |
| WO2005047860A2 (en) | 2003-11-08 | 2005-05-26 | Elan Pharmaceuticals, Inc. | Antibodies to alpha-synuclein |
| US20050203010A1 (en) | 2003-11-14 | 2005-09-15 | Atgen Co., Ltd. | Novel peptides conferring environmental stress resistance and fusion proteins including said peptides |
| SE0401601D0 (sv) | 2004-06-21 | 2004-06-21 | Bioarctic Neuroscience Ab | Protofibril specific antibodies and uses thereof |
| US7553639B2 (en) | 2006-01-31 | 2009-06-30 | Elan Pharma International Limited | Alpha-synuclein kinase |
| EP2325209A3 (en) | 2006-03-23 | 2011-08-03 | BioArtic Neuroscience AB | Improved protofibril selective antibodies and the use thereof |
| US8147833B2 (en) | 2007-02-23 | 2012-04-03 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
| CN101161245B (zh) * | 2007-11-29 | 2011-11-09 | 首都医科大学宣武医院 | 二苯乙烯苷及其衍生物抑制突触核蛋白过度表达的用途 |
| EP3470079A1 (en) * | 2008-04-29 | 2019-04-17 | BioArctic AB | Antibodies and vaccines for use in therapeutic and diagnostic methods for alpha-synuclein-related disorders |
| DK2448968T3 (da) | 2009-06-29 | 2021-04-12 | Bioarctic Ab | ANTISTOFFER SOM ER SELEKTIVE FOR N-TERMINAL-TRUNKEREDE AMYLOID-ß PROTOFIBRILLER/OLIGOMERER |
| ES2661925T3 (es) | 2010-02-26 | 2018-04-04 | Bioarctic Ab | Anticuerpos de unión a las protofibrillas y su uso en métodos terapéuticos diagnósticos para la enfermedad de Parkinson, la demencia con cuerpos de Lewy y otras alfa-sinucleinopatías |
-
2011
- 2011-02-25 ES ES11713058.3T patent/ES2661925T3/es active Active
- 2011-02-25 WO PCT/IB2011/050826 patent/WO2011104696A1/en not_active Ceased
- 2011-02-25 HR HRP20180230TT patent/HRP20180230T8/hr unknown
- 2011-02-25 RS RS20180129A patent/RS57029B1/sr unknown
- 2011-02-25 SM SM20180044T patent/SMT201800044T1/it unknown
- 2011-02-25 EP EP11713058.3A patent/EP2539366B1/en active Active
- 2011-02-25 LT LTEP11713058.3T patent/LT2539366T/lt unknown
- 2011-02-25 AU AU2011219414A patent/AU2011219414B2/en active Active
- 2011-02-25 SI SI201131419T patent/SI2539366T1/en unknown
- 2011-02-25 PT PT117130583T patent/PT2539366T/pt unknown
- 2011-02-25 CA CA2789963A patent/CA2789963C/en active Active
- 2011-02-25 US US13/578,710 patent/US8632776B2/en active Active
- 2011-02-25 CN CN201910950804.0A patent/CN110655573B/zh active Active
- 2011-02-25 HU HUE11713058A patent/HUE038313T2/hu unknown
- 2011-02-25 RU RU2012140954/10A patent/RU2555526C2/ru active
- 2011-02-25 PL PL11713058T patent/PL2539366T3/pl unknown
- 2011-02-25 CN CN201610801424.7A patent/CN106397588B/zh active Active
- 2011-02-25 JP JP2012554464A patent/JP5894939B2/ja active Active
- 2011-02-25 DK DK11713058.3T patent/DK2539366T3/en active
- 2011-02-25 CN CN201180011363.XA patent/CN102869680B/zh active Active
- 2011-02-25 NO NO11713058A patent/NO2539366T3/no unknown
-
2013
- 2013-08-01 US US13/957,239 patent/US8859501B2/en active Active
-
2014
- 2014-08-28 US US14/472,036 patent/US8968734B2/en active Active
-
2015
- 2015-02-02 US US14/611,690 patent/US9084832B2/en active Active
-
2018
- 2018-02-05 CY CY20181100140T patent/CY1120014T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LT2539366T (lt) | Protofibriles surišantys antikūnai ir jų panaudojimas parkinsono ligos, demencijos su levi kūneliais ir kitų alfa-sinukleinopatijų terapiniuose ir diagnostiniuose būduose | |
| LT2282758T (lt) | Antikūnai ir vakcinos, skirti su alfa sinukleinu susijusių sutrikimų gydymo ir diagnostiniams metodams | |
| ZA201300100B (en) | Indolizine derivatives,process for the preparation thereof and therapeutic use thereof | |
| ZA201209632B (en) | Imidazopyridine derivatives, process for the preparation thereof and therapeutic use thereof | |
| EP3043819A4 (en) | Anti-vstm5 antibodies and the use thereof in therapy and diagnosis | |
| AP2014007601A0 (en) | Novel purine derivatives and their use in the treatment of disease | |
| SI3333188T1 (sl) | Protitelesa proti NGF in njihova uporaba | |
| EP2656847A4 (en) | CONJUGATE FOR PHOTODYNAMIC DIAGNOSIS OR THERAPY AND PREPARATION METHOD THEREOF | |
| EP2523231A4 (en) | COMPOSITE PIEZOELECTRIC BODY, PROCESS FOR PRODUCING THE SAME, AND COMPOSITE PIEZOELECTRIC ELEMENT USING THE COMPOSITE PIEZOELECTRIC BODY | |
| GB201018014D0 (en) | Analytical methods and arrays for use in the same | |
| GB201217770D0 (en) | Biological probes and the use thereof | |
| ZA201204521B (en) | Beta-cell replication promoting compounds and methods of the their use | |
| EP2700654A4 (en) | HUMAN INSULIN AND ANALOG CONJUGATE THEREOF | |
| GB0918392D0 (en) | Diagnostic and therapeutic methods | |
| IL217209A0 (en) | Novel antibodies and their uses in therapeutic and diagnostic methods | |
| EP2836838A4 (en) | METHOD FOR DETERMINING A DISEASE ASSOCIATED WITH BREAST CANCER AND ARRAYS FOR USE IN THESE METHODS | |
| EP2528939A4 (en) | RECOMBINANT PROTEINS FOR USE IN VACCINES, ANTIBODIES TO THESE PROTEINS, AND DIAGNOSTIC AND THERAPEUTIC PROCEDURES THEREWITH | |
| EP2730585A4 (en) | PROTEIN-PEPTIDE COMPLEX HAVING SPECIFIC ACTION ON DERMAL TISSUES, PRODUCTION METHOD AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | |
| PL2453217T3 (pl) | Bezspoinowy korpus wagi oraz metoda jego produkcji | |
| ZA201306759B (en) | Compounds for use in imaging,diagnosing and/or treatment of diseases of the central nervous system | |
| IL226388A0 (en) | New indolizine derivatives, their preparation and medical use | |
| HK1170538A (en) | Novel antibodies and their uses in therapeutic and diagnostic methods | |
| HK1196617A (en) | Novel purine derivatives and their use in the treatment of disease | |
| IL244576A0 (en) | Anti-vstm5 antibodies and their use for treatment and diagnosis | |
| GB201001170D0 (en) | Novel peptides and their use in therepy and diagnosis |